XML 109 R95.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information - Schedule of Segment Results (Details)
€ in Millions
 6 Months Ended 12 Months Ended
Jun. 30, 2023
EUR (€)
segment
Jun. 30, 2022
EUR (€)
Dec. 31, 2022
EUR (€)
segment
Disclosure of operating segments [Line Items]      
Net sales € 20,187 € 19,790 € 42,997
Other revenues 1,358 1,005 2,392
Cost of sales (6,347) (6,130) (13,695)
Research and development expenses (3,193) (3,147) (6,706)
Selling and general expenses (5,182) (4,953) (10,492)
Net income attributable to non-controlling interests € 26 53 € 113
Number of operating segments | segment 2   3
Total      
Disclosure of operating segments [Line Items]      
Net sales € 20,187 19,790 € 42,997
Other revenues 1,358 1,005 2,392
Cost of sales (6,342) (6,127) (13,692)
Research and development expenses (3,193) (3,147) (6,706)
Selling and general expenses (5,182) (4,953) (10,492)
Other operating income and expenses (805) (788) (1,514)
Share of profit/(loss) from investments accounted for using the equity method 55 55 88
Net income attributable to non-controlling interests (19) (17) (33)
Business operating income 6,059 5,818 13,040
Biopharma      
Disclosure of operating segments [Line Items]      
Net sales 17,467 17,147 37,812
Other revenues 1,331 975 2,330
Cost of sales (5,388) (5,211) (11,793)
Research and development expenses (3,082) (3,062) (6,503)
Selling and general expenses (4,248) (4,081) (8,736)
Other operating income and expenses (897) (884) (1,679)
Share of profit/(loss) from investments accounted for using the equity method 48 47 76
Net income attributable to non-controlling interests (11) (8) (17)
Business operating income 5,220 4,923 11,490
Consumer Healthcare      
Disclosure of operating segments [Line Items]      
Net sales 2,720 2,643 5,185
Other revenues 27 30 62
Cost of sales (949) (925) (1,903)
Research and development expenses (111) (90) (205)
Selling and general expenses (936) (881) (1,761)
Other operating income and expenses 100 114 148
Share of profit/(loss) from investments accounted for using the equity method 7 8 12
Net income attributable to non-controlling interests (8) (9) (16)
Business operating income 850 890 1,522
Other      
Disclosure of operating segments [Line Items]      
Net sales 0 0 0
Other revenues 0 0 0
Cost of sales (5) 9 4
Research and development expenses 0 5 2
Selling and general expenses 2 9 5
Other operating income and expenses (8) (18) 17
Share of profit/(loss) from investments accounted for using the equity method 0 0 0
Net income attributable to non-controlling interests 0 0 0
Business operating income € (11) € 5 € 28